Petros Dimitriadis
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
From prediction to precision: Biomarker discovery and predictive modeling for personalized immune checkpoint blockade therapy.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 05, 2026
Dissecting response to neoadjuvant immunotherapy-treated melanoma using cancer-immunity cycle-associated signatures.
Journal: Cancer immunology, immunotherapy : CII
Published: April 23, 2025
Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicity.
Journal: Immunity
Published: April 15, 2025
Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma.
Journal: Communications medicine
Published: January 31, 2025
Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma.
Journal: Journal for immunotherapy of cancer
Published: March 25, 2024
Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma.
Journal: Cancer immunology, immunotherapy : CII
Published: September 30, 2023
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.
Journal: Journal for immunotherapy of cancer
Published: June 18, 2023
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma.
Journal: The Journal of experimental medicine
Published: November 14, 2022
Acidity-mediated induction of FoxP3+ regulatory T cells.
Journal: European journal of immunology
Published: November 07, 2022
Last Updated: 09/26/2026